Does the media prefer ALNY or HALO?

In the previous week, Alnylam Pharmaceuticals had 40 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 9 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral Halozyme Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HALO or BIIB?

In the previous week, Biogen had 54 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 68 mentions for Biogen and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat Biogen's score of 0.91 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 36 Very Positive mention(s) 5 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HALO or INCY?

In the previous week, Incyte had 35 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 49 mentions for Incyte and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat Incyte's score of 0.76 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 23 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HALO or UTHR?

In the previous week, United Therapeutics had 13 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 27 mentions for United Therapeutics and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat United Therapeutics' score of 1.10 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 20 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer NBIX or HALO?

In the previous week, Neurocrine Biosciences had 51 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 65 mentions for Neurocrine Biosciences and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat Neurocrine Biosciences' score of 0.92 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 24 Very Positive mention(s) 3 Positive mention(s) 23 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Halozyme Therapeutics (HALO) Competitors

$82.94 +0.41 (+0.49%)

As of 10:26 AM Eastern

Compare

HALO vs. ALNY, BIIB, INCY, UTHR, and NBIX

Should you buy Halozyme Therapeutics stock or one of its competitors? MarketBeat compares Halozyme Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Halozyme Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Halozyme Therapeutics has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	7.77	$313.75M	$5.38	40.11
Halozyme Therapeutics	$1.40B	7.04	$316.89M	$2.78	29.84

Alnylam Pharmaceuticals currently has a consensus price target of $404.57, indicating a potential upside of 87.49%. Halozyme Therapeutics has a consensus price target of $81.60, indicating a potential downside of 1.62%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.88
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

Alnylam Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

In the previous week, Alnylam Pharmaceuticals had 40 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 54 mentions for Alnylam Pharmaceuticals and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat Alnylam Pharmaceuticals' score of 0.06 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	9 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral
Halozyme Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 23.13% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Halozyme Therapeutics' return on equity of 187.91% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	104.81%	14.71%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Summary

Alnylam Pharmaceuticals beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Biogen?

Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Biogen had 54 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 68 mentions for Biogen and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat Biogen's score of 0.91 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	36 Very Positive mention(s)	5 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 23.13% compared to Biogen's net margin of 8.32%. Halozyme Therapeutics' return on equity of 187.91% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
Biogen	8.32%	11.18%	6.88%

Halozyme Therapeutics presently has a consensus price target of $81.60, suggesting a potential downside of 1.62%. Biogen has a consensus price target of $223.36, suggesting a potential upside of 10.36%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Halozyme Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biogen has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	7.04	$316.89M	$2.78	29.84
Biogen	$9.89B	3.02	$1.29B	$5.65	35.82

Summary

Biogen beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Incyte?

Halozyme Therapeutics (NASDAQ:HALO) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Incyte has higher revenue and earnings than Halozyme Therapeutics. Incyte is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	7.04	$316.89M	$2.78	29.84
Incyte	$5.82B	4.20	$1.29B	$7.85	15.36

Halozyme Therapeutics presently has a consensus price target of $81.60, indicating a potential downside of 1.62%. Incyte has a consensus price target of $119.60, indicating a potential downside of 0.78%. Given Incyte's higher possible upside, analysts clearly believe Incyte is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Incyte had 35 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 49 mentions for Incyte and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat Incyte's score of 0.76 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	23 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Incyte has a net margin of 27.71% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
Incyte	27.71%	29.93%	22.88%

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Incyte beats Halozyme Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Halozyme Therapeutics compare to United Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

United Therapeutics has higher revenue and earnings than Halozyme Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	7.04	$316.89M	$2.78	29.84
United Therapeutics	$3.18B	6.91	$1.33B	$27.09	19.12

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, United Therapeutics had 13 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 27 mentions for United Therapeutics and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat United Therapeutics' score of 1.10 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	20 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Halozyme Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to Halozyme Therapeutics' net margin of 23.13%. Halozyme Therapeutics' return on equity of 187.91% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
United Therapeutics	40.62%	19.24%	17.25%

Halozyme Therapeutics currently has a consensus target price of $81.60, indicating a potential downside of 1.62%. United Therapeutics has a consensus target price of $648.33, indicating a potential upside of 25.19%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe United Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

United Therapeutics beats Halozyme Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Neurocrine Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 23.13% compared to Neurocrine Biosciences' net margin of 20.91%. Halozyme Therapeutics' return on equity of 187.91% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Neurocrine Biosciences currently has a consensus price target of $201.05, indicating a potential upside of 18.13%. Halozyme Therapeutics has a consensus price target of $81.60, indicating a potential downside of 1.62%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Neurocrine Biosciences is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.96
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

Neurocrine Biosciences has higher revenue and earnings than Halozyme Therapeutics. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.98	$478.60M	$6.82	24.95
Halozyme Therapeutics	$1.40B	7.04	$316.89M	$2.78	29.84

In the previous week, Neurocrine Biosciences had 51 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 65 mentions for Neurocrine Biosciences and 14 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.17 beat Neurocrine Biosciences' score of 0.92 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	24 Very Positive mention(s)	3 Positive mention(s)	23 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurocrine Biosciences beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HALO vs. The Competition

Export

Metric	Halozyme Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.84B	$3.51B	$6.81B	$12.55B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	29.84	7.39	282.12	24.83
Price / Sales	7.04	1,209.27	573.08	78.59
Price / Cash	17.30	44.80	28.60	46.71
Price / Book	197.49	16.98	11.02	6.15
Net Income	$316.89M	-$12.56M	$3.49B	$347.61M
7 Day Performance	1.80%	-1.85%	0.47%	1.17%
1 Month Performance	4.40%	-8.52%	-4.24%	-3.46%
1 Year Performance	40.54%	47.51%	62.63%	19.43%

Halozyme Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HALO Halozyme Therapeutics	3.7157 of 5 stars	$82.95 +0.5%	$81.60 -1.6%	+39.9%	$9.84B	$1.40B	29.84	390	Positive News Upcoming Earnings Analyst Upgrade
ALNY Alnylam Pharmaceuticals	4.6995 of 5 stars	$278.40 +2.4%	$452.13 +62.4%	-48.9%	$36.28B	$3.71B	76.07	2,770	Trending News Analyst Forecast
BIIB Biogen	3.9455 of 5 stars	$200.14 -1.0%	$220.57 +10.2%	+53.8%	$29.85B	$9.89B	21.47	7,500	Earnings Report Analyst Downgrade Gap Up
INCY Incyte	2.8956 of 5 stars	$118.87 +1.0%	$111.10 -6.5%	+58.1%	$23.51B	$5.36B	16.79	2,844	Earnings Report Analyst Downgrade Gap Up
UTHR United Therapeutics	4.7137 of 5 stars	$527.94 -0.1%	$648.33 +22.8%	+75.9%	$22.43B	$3.18B	19.49	1,400	Positive News Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HALO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Competitors

HALO vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Halozyme Therapeutics compare to Biogen?

Summary

How does Halozyme Therapeutics compare to Incyte?

Summary

How does Halozyme Therapeutics compare to United Therapeutics?

Summary

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Competitors

HALO vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Do institutionals and insiders believe in ALNY or HALO?

Which has stronger earnings & valuation, ALNY or HALO?

Do analysts prefer ALNY or HALO?

Which has more risk & volatility, ALNY or HALO?

Does the media prefer ALNY or HALO?

Is ALNY or HALO more profitable?

Summary

How does Halozyme Therapeutics compare to Biogen?

Does the media favor HALO or BIIB?

Is HALO or BIIB more profitable?

Do analysts prefer HALO or BIIB?

Which has more volatility & risk, HALO or BIIB?

Do insiders and institutionals have more ownership in HALO or BIIB?

Which has preferable earnings and valuation, HALO or BIIB?

Summary

How does Halozyme Therapeutics compare to Incyte?

Which has preferable valuation & earnings, HALO or INCY?

Do analysts recommend HALO or INCY?

Does the media favor HALO or INCY?

Which has more volatility & risk, HALO or INCY?

Is HALO or INCY more profitable?

Do insiders & institutionals believe in HALO or INCY?

Summary

How does Halozyme Therapeutics compare to United Therapeutics?

Which has stronger earnings and valuation, HALO or UTHR?

Do institutionals and insiders believe in HALO or UTHR?

Does the media favor HALO or UTHR?

Which has more risk and volatility, HALO or UTHR?

Is HALO or UTHR more profitable?

Do analysts recommend HALO or UTHR?

Summary

How does Halozyme Therapeutics compare to Neurocrine Biosciences?

Which has more volatility & risk, NBIX or HALO?

Do institutionals & insiders hold more shares of NBIX or HALO?

Is NBIX or HALO more profitable?

Do analysts rate NBIX or HALO?

Which has better earnings and valuation, NBIX or HALO?

Does the media prefer NBIX or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools